These results show that oxygen may considerably boost the anti-HCC impact of selenium compounds by controlling the Nrf2 and MAPK signaling pathways, opening the door to selenium’s use in clinical therapy for hypoxic tumors [45]. The gene discussed is NFE2L2; the disease is hepatocellular carcinoma.